相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Homologous and Heterologous Covid-19 Booster Vaccinations
R. L. Atmar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Adolescents, Children, and Infants: A Systematic Review and Meta-Analysis
Yuxuan Du et al.
FRONTIERS IN PUBLIC HEALTH (2022)
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
Anahita Fathi et al.
NATURE COMMUNICATIONS (2022)
Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis
Juntao Yin et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)
Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
Naif Khalaf Alharbi et al.
VACCINES (2022)
BNT162b2 Vaccine Booster and Covid-19 Mortality
Thomas Rohban
NEW ENGLAND JOURNAL OF MEDICINE (2022)
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
Ann R. Falsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Comparison of four heterogeneity measures for meta-analysis
Lifeng Lin
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2020)
The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?
Noah C. Peeri et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2020)
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open -label, phase 1 trial
Till Koch et al.
LANCET INFECTIOUS DISEASES (2020)
A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques
Neeltje van Doremalen et al.
SCIENCE ADVANCES (2020)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Pedro M. Folegatti et al.
LANCET (2020)
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Kizzmekia S. Corbett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Maheshi N. Ramasamy et al.
LANCET (2020)
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
Kayvon Modjarrad et al.
LANCET INFECTIOUS DISEASES (2019)
Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus
Myung Hee Kim et al.
PLOS ONE (2019)
Coronaviruses - drug discovery and therapeutic options
Alimuddin Zumla et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease
Jasper F. W. Chan et al.
CLINICAL MICROBIOLOGY REVIEWS (2015)
Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015
B. J. Cowling et al.
EUROSURVEILLANCE (2015)
Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge
Jiaming Lan et al.
EBIOMEDICINE (2015)
Middle East respiratory syndrome (MERS) A new zoonotic viral pneumonia
Cheston B. Cunha et al.
VIRULENCE (2014)